| Matthew D Olson, MD | |
|
1229 C Ave E, Oskaloosa, IA 52577-4246 | |
| (641) 672-3100 | |
| (641) 672-3111 |
| Full Name | Matthew D Olson |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 1229 C Ave E, Oskaloosa, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033372347 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Guttenberg Municipal Hospital | Guttenberg, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Guttenberg Municipal Hospital | 6901709476 | 20 |
| Guttenberg Municipal Hospital | 6901709476 | 20 |
News Archive
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.
Neighborhood violence has been associated with adverse health effects on youth, including sleep loss, asthma and metabolic syndrome. Yet some youth living in high-crime neighborhoods manage to avoid these effects.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.
Cancer causing high-risk human papillomaviruses (HR-HPV) are responsible for the rising incidence of HR-HPV–driven head and neck cancers (HNC), particularly oropharyngeal cancers (OPC, or throat cancers). Investigators have determined that HR-HPV DNA can be detected in saliva in most patients with HPV-driven OPC at the time of diagnosis. This work highlights a potentially life-saving screening program based on salivary HR-HPV DNA testing for early cancer detection and patient monitoring. Their findings appear in The Journal of Molecular Diagnostics, published by Elsevier.
› Verified 2 days ago
| Entity Name | Prairie Du Chien Memorial Hospital Association, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619024197 PECOS PAC ID: 4981698537 Enrollment ID: O20040414001308 |
News Archive
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.
Neighborhood violence has been associated with adverse health effects on youth, including sleep loss, asthma and metabolic syndrome. Yet some youth living in high-crime neighborhoods manage to avoid these effects.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.
Cancer causing high-risk human papillomaviruses (HR-HPV) are responsible for the rising incidence of HR-HPV–driven head and neck cancers (HNC), particularly oropharyngeal cancers (OPC, or throat cancers). Investigators have determined that HR-HPV DNA can be detected in saliva in most patients with HPV-driven OPC at the time of diagnosis. This work highlights a potentially life-saving screening program based on salivary HR-HPV DNA testing for early cancer detection and patient monitoring. Their findings appear in The Journal of Molecular Diagnostics, published by Elsevier.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Matthew D Olson, MD 1229 C Ave E, Oskaloosa, IA 52577-4246 Ph: (641) 672-3100 | Matthew D Olson, MD 1229 C Ave E, Oskaloosa, IA 52577-4246 Ph: (641) 672-3100 |
News Archive
PlasmaTech Biopharmaceuticals, Inc., a biopharmaceutical company advancing patient care in critical areas, has entered into an exclusive license agreement with Norgine B.V., a European specialist pharmaceutical company, for the commercialization of MuGard in Australia and New Zealand.
Neighborhood violence has been associated with adverse health effects on youth, including sleep loss, asthma and metabolic syndrome. Yet some youth living in high-crime neighborhoods manage to avoid these effects.
BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.
Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.
Cancer causing high-risk human papillomaviruses (HR-HPV) are responsible for the rising incidence of HR-HPV–driven head and neck cancers (HNC), particularly oropharyngeal cancers (OPC, or throat cancers). Investigators have determined that HR-HPV DNA can be detected in saliva in most patients with HPV-driven OPC at the time of diagnosis. This work highlights a potentially life-saving screening program based on salivary HR-HPV DNA testing for early cancer detection and patient monitoring. Their findings appear in The Journal of Molecular Diagnostics, published by Elsevier.
› Verified 2 days ago
Shawn Michael Richmond, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 410 N 12th St, Oskaloosa, IA 52577 Phone: 641-672-3360 Fax: 641-672-2258 | |
Charles R Argo, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 410 N 12th St, Suite 300, Oskaloosa, IA 52577 Phone: 641-672-2571 | |
Anna Marie Throckmorton, ARNP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3160 | |
Tony R Kunz, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 410 N 12th St, Suite 300, Oskaloosa, IA 52577 Phone: 641-672-2571 | |
Anne K Whitis, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 410 N 12th St, Suite 300, Oskaloosa, IA 52577 Phone: 641-672-2571 | |
Mark Zacharjasz, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1229 C Ave E, Oskaloosa, IA 52577 Phone: 641-672-3100 |